Journal article
Interaction between polymorphisms in aspirin metabolic pathways, regular aspirin use and colorectal cancer risk: A case-control study in unselected white European populations
H Sheth, E Northwood, CM Ulrich, D Scherer, F Elliott, JH Barrett, D Forman, C Roland Wolf, G Smith, MS Jackson, M Santibanez-Koref, R Haile, G Casey, M Jenkins, AK Win, JL Hopper, L Le Marchand, NM Lindor, SN Thibodeau, JD Potter Show all
Plos One | PUBLIC LIBRARY SCIENCE | Published : 2018
Abstract
Regular aspirin use is associated with reduced risk of colorectal cancer (CRC). Variation in aspirin's chemoprevention efficacy has been attributed to the presence of single nucleotide polymorphisms (SNPs). We conducted a meta-analysis using two large population-based case-control datasets, the UK-Leeds Colorectal Cancer Study Group and the NIH-Colon Cancer Family Registry, having a combined total of 3325 cases and 2262 controls. The aim was to assess 42 candidate SNPs in 15 genes whose association with colorectal cancer risk was putatively modified by aspirin use, in the literature. Log odds ratios (ORs) and standard errors were estimated for each dataset separately using logistic regressio..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
The UK-CCSG study was supported by the Cancer Research UK grant C588/A19167. The NIH-CCFR study was supported by grant UM1 CM 67551 from the National Cancer Institute and through cooperative agreements with the following CCFR centers: Australasian Colorectal Cancer Family Registry (U01 CA074778 and U01/U24 CA097735), Ontario Familial Colorectal Cancer Registry (U01/U24 CA074783) and Seattle Colorectal Cancer Family Registry (U01/U24 CA074794). The Colon CFR Illumina GWAS was supported by funding from the National Cancer Institute, National Institutes of Health (U01 CM 22839 and R01 CA143237 to Graham Casey). The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centres in the Colon Cancer Family Registry (CCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the CCFR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.